RxDoctor Payments Data

Robert Bazylak, MD

Family Medicine · Meadville, PANPI 1285614263

Payments from drug & device makers

$15,335in general payments, 2019–2025

Across 1,032 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Novartis$894
  • plus $8K from 36 others

What the payments were for

  • Food & beverage$15,292100%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,335 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,393
Medicare patients
233
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$88,731
XareltoRivaroxaban59$73,570
JardianceEmpagliflozin61$71,535
MounjaroTirzepatide63$67,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$36,223
TrulicityDulaglutide24$32,137
JanuviaSitagliptin Phosphate21$26,171
RybelsusSemaglutide12$23,487
OzempicSemaglutide28$23,250
VascepaIcosapent Ethyl30$15,902
Colesevelam Hcl16$6,392
TradjentaLinagliptin11$5,652
Atorvastatin Calcium431$5,617
Spiriva HandihalerTiotropium Bromide11$5,253
Omega-3 Acid Ethyl Esters66$4,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,235$99,98887 claims
PfizerEliquis$1,133$88,73177 claims
Boehringer IngelheimJardiance, Tradjenta$398$77,18772 claims
Johnson & JohnsonXarelto$693$73,57059 claims
Novo NordiskRybelsus, Ozempic$1,788$46,73840 claims
GSKTrelegy Ellipta$1,338$36,22353 claims
MerckJanuvia$830$26,17121 claims
AstraZenecaSymbicort$809$2,37511 claims
Sanofi-aventis U.S. LLCLantus$141$1,33522 claims
AbbVieSynthroid$1,330$1,16517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Meadville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →